• Expected NDA filing mid-2014.
• Granted Orphan designation by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma. If approved, will be the only drug approved for this indication.
• In a previous clinical study, Captisol-enabled melphalan met the requirements for establishment of bioequivalence to the current commercial intravenous formulation of melphalan.

Henderson, NV (Press Release) - Spectrum Phar­ma­ceu­ti­cals (NasdaqGS: SPPI), a bio­technology com­pany with fully integrated commercial and drug devel­op­ment operations and a pri­mary focus in hematology and …